RxDoctor Payments Data

Deborah Varnam

Family · Shallotte, NCNPI 1922075910

Payments from drug & device makers

$659in general payments, 2019–2025

Across 38 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$280
  • Amgen$111
  • Novo Nordisk$82
  • Lilly USA, LLC$60
  • Pfizer$49
  • AbbVie$36
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$61493%
  • Education$457%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$659 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$84,551
Medicare patients
161
Services billed
2,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$96,153
Invega SustennaPaliperidone Palmitate11$35,879
EliquisApixaban40$35,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$27,030
JanuviaSitagliptin Phosphate17$24,175
SymbicortBudesonide/Formoterol Fumarate69$22,880
XareltoRivaroxaban27$22,233
FarxigaDapagliflozin Propanediol17$20,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$16,027
Spiriva HandihalerTiotropium Bromide12$13,541
RybelsusSemaglutide13$12,044
ArexvyRsvpref3 Antigen/As01e/Pf37$11,895
Xtampza ErOxycodone Myristate16$10,073
ConcertaMethylphenidate Hcl12$9,551
ShingrixVaricella-Zoster Ge/As01b/Pf40$9,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$82$108,19891 claims
AstraZenecaSymbicort, Farxiga, Breztri Aerosphere$280$59,247100 claims
PfizerEliquis$49$35,24740 claims
AbbVieSynthroid$36$2,82726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Shallotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →